BUZZ-在罕见眼癌试验中,联合用药显示出生存优势,Ideaya 公司业绩上升

路透中文
Oct 20, 2025
BUZZ-在罕见眼癌试验中,联合用药显示出生存优势,Ideaya 公司业绩上升

10月20日 - ** 加州药物开发商Ideaya BiosciencesIDYA.O股价盘前上涨7.3%至31.40美元

** 该公司称,在一项中期研究中接受 darovasertib和辉瑞的Xalkori组合治疗 的罕见眼癌患者 的中位总生存期为21.1个月

** 根据已公布的数据,转移性葡萄膜黑色素瘤(一种罕见眼癌)的生存期通常为12个月左右 - IDYA

** 中位生存期是指患某种疾病的患者中,50%仍然存活,50%已经死亡的时间长度。

** IDYA 称,试验显示 44 名患者的反应率为 34%,疾病控制率为 90%;中位反应持续 9 个月

** 5%以上的患者未出现严重副作用;最常见的副作用是恶心、疲劳、皮疹 - IDYA

** 经纪公司Leerink Partners称,OS数据处于先前指导的高端,增强了对后期试验成功的信心

** 截至上次收盘,股价年累计上涨约 14

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10